 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2608 News |  |
| «12...89101112131415161718...3132» |
- teriflunomide / Generic mfg.
Predictive Factors of Response to Teriflunomide in Patients with Multiple Sclerosis (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_424;
According to our data and as previously reported, teriflunomide is shown as an effective and well tolerated drug for Multiple Sclerosis. We found a higher rate of responders in naïve patients, without any statistically significant differences in the rest of variables studied.
- Mavenclad (cladribine) / EMD Serono
Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_416;
For all three pairwise comparisons, relapse and discontinuation outcomes significantly favored CladT over other oral DMTs. Future analyses with longer follow-up comparing disability progression events are warranted.
- glatiramer acetate / Generic mfg.
7T MRI is More Sensitive to Leptomeningeal Contrast Enhancement in MS than 3T MRI: a Direct Comparison (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_346;
Our findings are consistent with cross-study comparisons suggesting that 7T MRI is more sensitive to LME than 3T MRI, presumably due to increased sensitivity to contrast. LMEs identified at 7T were all sufficiently large for MRI spatial resolution to not have been a limiting factor to their detection at 3T.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Humoral and cellular immune response after SARS CoV-2 vaccine in patients with Multiple Sclerosis treated with immunosuppressant (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_291;
Eighty patients were evaluated in treatment with: 10 teriflunomide, 6 dimethyl fumarate, 13 cladribine, 8 fingolimod, 7 natalizumab, 27 ocrelizumab, 4 alemtuzumab, 5 rituximab... In our cohort the majority of immunosuppressed MS patients who are not capable of inducing an adequate humoral response, present a cellular immune response after administration of the SARS CoV-2 vaccine.
- teriflunomide / Generic mfg.
A Propos of a Case with Multiple Sclerosis Associated with Balò-like Lesions Post-COVID-19 (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_289;
Post-COVID-19, our patient’s MRI demonstrated other lesion morphologies, potentially reflecting different pathologies. Intra-individual pathological heterogeneity has been debated.
- Mavenclad (cladribine) / EMD Serono
Influence of disease modifying treatments on humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_287;
The humoral response to SARS-CoV-2 mRNA vaccines is preserved in untreated MS patients and those treated with cladribine and teriflunomide, but reduced under anti-CD20 antibodies and S1P-modulators. Within patients under treatment with anti-CD20 antibodies, delaying vaccinations to more than 6 months after last dose and wait for B cell repopulation are potential strategies to optimize humoral response to vaccines.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Effects of Multiple Sclerosis Disease-Modifying Therapies on Immunological Responses to COVID-19 Vaccination in Hispanic Puerto Rican Patients (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_283;
At present, there is limited research on the response to these novel mRNA vaccines among Hispanic Puerto Rican MS patients receiving different DMTs. Nonetheless, we are still awaiting the immunological responses from 1 month after the booster dose of the mRNA vaccine and 1 year (after the second dose of the mRNA vaccine).
- Mavenclad (cladribine) / EMD Serono
Humoral immune response to SARS-Cov2 in treated MS patients (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_280;
The adverse events on MS patients were similar to the general population. No increase of relapse activity was observed.Most of MS treated patients developed enough antibodies to SARS-CoV-2.Some patients treated with ocrelizumab , rituximab and fingolimod have no developed a humoral response to SARS-CoV-2 vaccination.Vaccination strategy in patients treated with anti-CD20 and fingolimod need further studies.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Humoral Immune Response to COVID-19 Vaccines, Dynamics of Antibodies and Levels of Seroprotection in Patients with Multiple Sclerosis Receiving Different Disease Modifying Treatments (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_276;
pwMS without therapy or on DMTs other than anti-CD20s and S1Ps developed adequate humoral immune response against SARS-CoV-2, similar to HCs, with seroprotective Ab titers throughout the 16-week observation period. Higher absolute CD19+ cell count at time of vaccination and longer interval since last infusion in the anti-CD20 group as well as normal ALC in the S1Ps group, were associated with a more favorable humoral response to vaccination.
- dimethyl fumarate / Generic mfg.
Immune response to COVID-19 vaccination in MS Patients on Disease Modifying Therapy and Correlation with B-Cell Reconstitution and Clinical Outcomes (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_270;
Patients on B-cell therapies and S1P inhibitors have significantly lower levels of SARS-CoV-2 spike antibodies following vaccination. This study seeks to further understand the relationship of these lab values with B-cell reconstitution and real-world clinical outcomes.
- Mavenclad (cladribine) / EMD Serono
Influence of disease modifying treatments on humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_266;
The humoral response to SARS-CoV-2 mRNA vaccines is preserved in untreated MS patients and those treated with cladribine and teriflunomide, but reduced under anti-CD20 antibodies and S1P-modulators. Within patients under treatment with anti-CD20 antibodies, delaying vaccinations to more than 6 months after last dose and wait for B cell repopulation are potential strategies to optimize humoral response to vaccines.
- glatiramer acetate / Generic mfg.
Familial Mediterranean Fever as a Risk Factor and Comorbidity in MS: Case Report and Systematic Review of Treatment Approach (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_264;
FMF severity does not seem to correlate with MS risk as most reviewed cases reported stable FMF managed with colchicine alone prior to MS onset. Multi-centered prospective studies are needed to investigate whether a particular DMT class may be most beneficial for concurrent management in this patient population.
- Ponvory (ponesimod) / J&J
Optimum Trial Patients Treated With Ponesimod Show Less Ventricular Enlargement Over Time Compared To Patients Treated With Teriflunomide (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_251;
Increase in ventricular volume throughout the double-blind phase was observed for both ponesimod and teriflunomide treated patients. However, the rate of increase on ponesimod was 60% lower at week 60 and 46% lower at week 108 compared to teriflunomide, suggesting a reduced rate of neurodegeneration on ponesimod, as measured by MRI-based ventricular volume.
- Utuxin (ublituximab) / TG Therap
Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_249;
In the Phase 3 ULTIMATE I and II studies in patients with relapsing multiple sclerosis (RMS), ublituximab significantly reduced relapse rate, the number of gadolinium-enhanced T1 lesions, and new or enlarging T2 lesions vs teriflunomide at 96 weeks. In ULTIMATE I and II, peripheral B-cell numbers declined rapidly after the first ublituximab infusion and remained low during treatment, which is consistent with ublituximab’s mechanism of action.
- Utuxin (ublituximab) / TG Therap
Neutralizing Antibodies and Antidrug Antibodies in the Ublituximab Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_248;
The proportion of patients with TE-NAbs declined after 24 weeks. TE-ADAs were generally transient and had no observable impact on the safety or efficacy of ublituximab.
- Utuxin (ublituximab) / TG Therap
Reduction in T1 Hypointense Lesions With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_245;
TE-ADAs were generally transient and had no observable impact on the safety or efficacy of ublituximab. In pooled post hoc analyses, significant reductions in both the volume and number of new T1 hypointense lesions were seen with ublituximab vs teriflunomide at 96 weeks.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Relative Differences in Brain Volume Loss With Teriflunomide Versus Other Disease-Modifying Therapies in Relapsing Multiple Sclerosis: a Systematic Review and Network Meta-Analysis (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_238;
This study provides an initial understanding of comparative BVL for patients with RMS, encompassing an outcome not previously assessed in NMAs. Most DMTs were similar in their reductions in BVL when compared with teriflunomide, with some evidence favoring teriflunomide at 12 and 24 months.
- dimethyl fumarate / Generic mfg.
Spinal Cord Lesions as a Possible Predictor of Lack of Response to First-Line Disease Modifying Therapies in Treatment-Naïve Multiple Sclerosis Patients (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_236;
Patients with SCL at diagnosis, specially if higher number of SCL or Gd+ SCL showed a tendency to worse response to these therapies. Confirmation of our findings with a bigger population and longer follow-up is warranted.
- Ponvory (ponesimod) / J&J
Prognostic Value of the MAGNIMS Score and its Application in Clinical Outcome Assessment of Disease Modifying Therapy in Patients with Relapsing Multiple Sclerosis: Results from the OPTIMUM Study of Ponesimod (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_229;
These results further validate that the MAGNIMS score has the potential to predict the long-term risk of disability worsening and can be a useful tool for clinicians to identify patients early with a suboptimal response to a newly-initiated DMT. Treatment with ponesimod was found to result in more patients classified with a favorable MAGNIMS score at week 60 than teriflunomide, but the long-term effect on CDA between these treatments needs to be further confirmed in future research.
- Ponvory (ponesimod) / J&J
Results of the Phase 3 OPTIMUM Study of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis (Exhibit Hall A) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_227;
PON was also more effective at achieving no evidence of disease activity status. The safety profile was similar with previous safety observations of other S1P receptor modulators.
- || Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Review, Journal: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. (Pubmed Central) - Feb 19, 2022
There was no apparent association between changes in immunoglobulin G or M levels and the risk of serious infections after 3.5 years of ofatumumab treatment. Thus, ofatumumab is a convenient treatment option that is effective and has a generally manageable tolerability profile in adults with relapsing forms of MS.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia. (Pubmed Central) - Feb 19, 2022
New DMTs are not as readily available in Croatia as they are in some countries. However, there is a continuous increase in the number of prescriptions, along with growing costs in pharmacological treatment of multiple sclerosis, and this can be expected to become even more pronounced in the following years, due to the abundance of new therapeutic options that are steadily becoming available.
- | teriflunomide / Generic mfg.
Journal: Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis. (Pubmed Central) - Feb 16, 2022
This supports the recommendations found in the United States Product Insert (USPI) stating that men taking teriflunomide who do not wish to father a child, and their female partners, should use reliable contraception. Men wishing to father a child should discontinue use of teriflunomide and undergo an accelerated elimination procedure to reduce the plasma concentrations of the medication to less than 0.02 mg/L (0.02 µg/ml.
- | teriflunomide / Generic mfg.
Journal: Thematic analysis of multiple sclerosis research by enhanced strategic diagram. (Pubmed Central) - Feb 16, 2022
The emerging keywords identified utilising the enhanced strategic diagram were 'covid-19', 'teriflunomide', 'clinical trial', 'microglia', 'b cells', 'myelin', 'brain', 'white matter', 'functional connectivity', 'pain', 'employment', 'health-related quality of life', 'meta-analysis' and 'comorbidity'. This study demonstrates the tremendous growth of multiple sclerosis literature worldwide, which is expected to grow more than double during the next decade especially in the identified emerging topics.
- | teriflunomide / Generic mfg.
Trial completion date, Trial primary completion date: Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (clinicaltrials.gov) - Feb 15, 2022
P1/2, N=16, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
This study demonstrates the tremendous growth of multiple sclerosis literature worldwide, which is expected to grow more than double during the next decade especially in the identified emerging topics. Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2024
- Utuxin (ublituximab) / TG Therap
Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) () - Feb 14, 2022 - Abstract #AAN2022AAN_665;
Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2024 In the Phase 3 ULTIMATE I and II trials, relapse rate and cumulative probability of relapse were significantly reduced with ublituximab vs teriflunomide.
- |||||||||| remibrutinib (LOU064) / Novartis
New P3 trial: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib (EUDRACT) - Feb 12, 2022
P3, N=800, Ongoing, Sponsor: Novartis Farmacéutica S.A.
- |||||||||| remibrutinib (LOU064) / Novartis
New P3 trial: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib (EUDRACT) - Feb 12, 2022
P3, N=800, Ongoing, Sponsor: Novartis Farmac
- | teriflunomide / Generic mfg.
Journal: Teriflunomide Promotes Oligodendroglial 8,9-Unsaturated Sterol Accumulation and CNS Remyelination. (Pubmed Central) - Feb 5, 2022
In the Phase 3 ULTIMATE I and II trials, relapse rate and cumulative probability of relapse were significantly reduced with ublituximab vs teriflunomide. TF enhances zymosterol accumulation in oligodendrocytes and CNS myelin repair, a beneficial off-target effect that should be investigated in patients with multiple sclerosis.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Review, Journal: The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. (Pubmed Central) - Feb 4, 2022
In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sclerosis, including beta interferon, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, cladribine, natalizumab, alemtuzumab, and ocrelizumab...For some DMTs, screening for hepatitis B virus and hepatitis C virus is required before starting treatment and a monitoring or antiviral prophylaxis schedule has been established. Beta interferon, glatiramer acetate, natalizumab, and alemtuzumab are relatively contraindicated in autoimmune hepatitis due to the risk of disease exacerbation.
- || teriflunomide / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: AUBACOG: Cognition and MRI Markers in MS Patients With Aubagio (clinicaltrials.gov) - Feb 3, 2022
P=N/A, N=75, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Beta interferon, glatiramer acetate, natalizumab, and alemtuzumab are relatively contraindicated in autoimmune hepatitis due to the risk of disease exacerbation. Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Nov 2022 | Trial primary completion date: May 2023 --> Nov 2022
- |||| teriflunomide / Generic mfg., vidofludimus (IMU-838) / Immunic, leflunomide / Generic mfg.
Clinical: Another criticism would be that IMU-838 is just a "me too" drug (DHODH inhibitor similar to Aubagio or Arava). What exactly does it add to the market? How would it benefit people with MS? (Twitter) - Jan 31, 2022
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. (Pubmed Central) - Jan 27, 2022
Teriflunomide, a first-line oral drug used in the treatment of relapsing-remitting MS (RRMS), may display antiviral activity by depleting cellular nucleotides necessary for viral replication...For example, fingolimod, might be highly beneficial during the hyperinflammatory stage of COVID-19 for a number of mechanisms including the reinforcement of the endothelial barrier. Caution is suggested for the use of natalizumab, cladribine, alemtuzumab, and ocrelizumab, although MS disease recurrence after discontinuation of these drugs may overcome a potential risk for COVID-19 infection.
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Clinical data, Journal: Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. (Pubmed Central) - Jan 27, 2022
Caution is suggested for the use of natalizumab, cladribine, alemtuzumab, and ocrelizumab, although MS disease recurrence after discontinuation of these drugs may overcome a potential risk for COVID-19 infection. Initiating MS-therapy with heDMT significantly reduced the risk of 5-year disability progression and relapse compared to using meDMT as first DMT choice in propensity-matched groups of Finnish MS-patients.
- | teriflunomide / Generic mfg.
Journal: Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment. (Pubmed Central) - Jan 26, 2022
Notably, 13t displayed significant tumor growth inhibition activity with a tumor growth inhibition (TGI) rate of 81.4% at 30 mg/kg in a Raji xenograft model. Together, 13t is a promising inhibitor of hDHODH and a preclinical candidate for antitumor therapy, especially for lymphoma.
- | teriflunomide / Generic mfg.
Journal: Teriflunomide Reduced Lesions in Pediatric Multiple Sclerosis. (Pubmed Central) - Jan 26, 2022
Together, 13t is a promising inhibitor of hDHODH and a preclinical candidate for antitumor therapy, especially for lymphoma. No abstract available
- || teriflunomide / Generic mfg.
Clinical, Journal: Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases. (Pubmed Central) - Jan 15, 2022
The estimated prevalence of pulmonary embolism in our cohort is 2.8%. Thus, we believe additional attention to the general risk factors for PE is warranted before teriflunomide is introduced to patients with multiple sclerosis.
- || teriflunomide / Generic mfg.
Clinical, Journal: Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. (Pubmed Central) - Jan 15, 2022
A total of 1994 Danish patients (92.3%) initiated a low to moderately effective DMT (teriflunomide, 907 [42.0%]) and 165 (7.6%) initiated a highly effective DMT, whereas a total of 1769 Swedish patients (65.5%) initiated a low to moderately effective DMT (teriflunomide, 64 [2.4%]) and 931 (34.5%) initiated a highly effective DMT...The findings of this study suggest that there is an association between differences in treatment strategies for RRMS and disability outcomes at a national level. Escalation of treatment efficacy was inferior to using more efficacious DMT as initial treatment.
- | teriflunomide / Generic mfg.
Journal: Carbon-13 Synthesis and NMR Spectroscopic Geometric Isomer Evaluation to Support the Filing of Teriflunomide. (Pubmed Central) - Jan 12, 2022
To get insights into the E/Z ratio of teriflunomide under "in-vivo" conditions, advanced heteronuclear NMR (HOESY) in D O and mixtures of D O/plasma were performed. While NMR experiments in mixtures of water and plasma failed due to extreme line broadening, NMR spectra in water at pH 7.4, showed only the Z-isomer.
- ||| Ponvory (ponesimod) / J&J
Clinical, P3 data, Journal: Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (Pubmed Central) - Jan 12, 2022
P3
The safety profile was in line with the previous safety observations with ponesimod and the known profile of other S1P receptor modulators. ClinicalTrials.gov Identifier: NCT02425644.
- | Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (clinicaltrials.gov) - Jan 12, 2022
P4, N=41, Active, not recruiting, Sponsor: Providence Health & Services
ClinicalTrials.gov Identifier: NCT02425644. Recruiting --> Active, not recruiting | N=70 --> 41 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: May 2018 --> Apr 2021
- || Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. (Pubmed Central) - Jan 7, 2022
We did not observe a statistically significant difference in response between patients treated with the other drugs (dimethyl fumarate, interferon, alemtuzumab and glatiramer acetate) and untreated patients...Humoral response to BNT162b2 is significantly influenced by the specific DMTs followed by patients, as well as by other factors such as previous SARS-CoV-2 infection, age, sex, and smoking status. These results are important to inform targeted strategies to prevent clinically relevant COVID-19 in MS patients.
- | leflunomide / Generic mfg.
Journal: Effect of the intramolecular hydrogen bond in the active metabolite analogs of leflunomide for blocking the Plasmodium falciparum dihydroorotate dehydrogenase enzyme: QTAIM, NBO, and docking study. (Pubmed Central) - Jan 4, 2022
For strong IHBs (E>100kJ/mol), C=O and O-H group are involved in the intramolecular interactions and do not contribute to the external interactions. Also, the docking study revealed maximum binding energy between TFM-Z and PfDHODH enzyme.
- || glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Clinical, Journal: Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. (Pubmed Central) - Jan 4, 2022
Switching from injectable platform therapies to oral first-line therapies in patients with clinically stable RRMS does not increase the risk of disability accumulation. While the postswitch risk of relapses trended towards marginally higher on TFL, this trend was eliminated by adjustment for time-variant confounders.
- || dimethyl fumarate / Generic mfg.
Clinical, Retrospective data, Journal, HEOR, Real-world evidence: Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia. (Pubmed Central) - Jan 3, 2022
There were 40 patients on the orally administered agents (e.g., dimethyl fumarate, teriflunomide, fingolimod), 66 patients were on IFN-based therapy (e.g., Rebif), and 40 patients were on monoclonal antibodies (e.g., rituximab and natalizumab)...Orally administered agents resulted in better outcomes and lower costs in comparison to IFN-based therapy. Future studies should further examine the cost-effectiveness of different disease-modifying therapies for the management of RRMS using more robust study designs.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. (Pubmed Central) - Dec 30, 2021
MS-specialist neurologist has to face new challenges regarding the management of immunosuppression-related infectious complications. The implementation of patient-centered management focus on preventive and mitigating strategies with a multidisciplinary approach should be seen in the future as a marker of excellence of MS management.
- | Lemtrada (alemtuzumab) / Sanofi
Journal, HEOR: Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis. (Pubmed Central) - Dec 30, 2021
This microsimulation model overcomes the limitation of previous models by modeling treatment sequences. Because it better reflects clinical reality, it facilitates incorporating cost-utility information in clinical guidelines.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. (Pubmed Central) - Dec 28, 2021
No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment...Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions.
- || Tysabri (natalizumab) / Biogen
Clinical, Journal: The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide. (Pubmed Central) - Dec 27, 2021
P4
There were no cases of PML. The washout-free transition of NTZ to TFM was an efficacious and safe strategy for patients at risk of developing PML.ClinicalTrials.gov Identifier: NCT01970410.